ClinicalTrials.Veeva

Menu

An Electronic Data Capture Study to Assess the Long-term Performance of the DePuy PROXIMA™ Hip in Primary Total Hip Replacement

DePuy Synthes logo

DePuy Synthes

Status and phase

Terminated
Phase 4

Conditions

Osteoarthritis
Congenital Hip Dysplasia
Avascular Necrosis
Post-traumatic Arthritis
Traumatic Femoral Fractures
Rheumatoid Arthritis

Treatments

Device: DePuy Proxima™ Hip

Study type

Interventional

Funder types

Industry

Identifiers

NCT01134445
CT07/02

Details and patient eligibility

About

The purpose of this study is to monitor the performance of the DePuy PROXIMA™ hip in the treatment of patients with hip joint disease requiring a total hip replacement. Patients who enter the study will be evaluated at regular intervals following hip surgery using patient, clinical and x-ray assessments.

Enrollment

42 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or female subjects between 18 and 70 years of age.
  • Subjects who are able to give voluntary, written informed consent to participate in this investigation and from whom consent has been obtained.
  • Subjects who, in the opinion of the Investigator, are able to understand this investigation, co-operate with the investigational procedures and agree to return to the hospital for all the required post-operative follow-ups.
  • Subjects who are scheduled to undergo a primary THR whom the surgeon considers to be suitable for the DePuy PROXIMATM hip femoral prosthesis.

Exclusion criteria

  • Subjects with active local or systemic infection
  • Subjects with loss of musculature, neuromuscular compromise or vascular deficiency in the affected limb rendering the procedure unjustified.
  • Subjects with poor bone quality, such as osteoporosis, where, in the surgeon's opinion, there could be considerable migration of the prosthesis or a significant chance of fracture of the femoral shaft and/or the lack of adequate bone to support the implant(s).
  • Subjects with Charcot's or Paget's disease.
  • Subjects with hip dysplasia with severe neck anteversion or severe dysplasia of the proximal femur.
  • Subjects with severe osteoporosis.
  • Subjects with previous proximal femoral fractures.
  • Subjects who, in the opinion of the Investigator, have an existing condition/co-morbidity or infection that would compromise their long-term participation and follow-up in this study.
  • Women who are pregnant.
  • Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes.
  • Subjects who have participated in a clinical study with an investigational product in the last 6 month(s).
  • Subjects who are currently involved in any injury litigation claims.
  • Subjects for whom the surgical procedure is a revision of a previous THR, hemi-arthroplasty or hip resurfacing
  • Subjects who have previously undergone osteotomy or arthrodesis of the hip.
  • Subjects undergoing a simultaneous bilateral hip operation.
  • Subjects undergoing the second stage of a staged bilateral for whom the contralateral hip is part of this clinical investigation.
  • Subjects undergoing the second stage of a staged bilateral for whom the contralateral hip was implanted less than six months previously or is not performing satisfactorily

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

42 participants in 1 patient group

DePuy Proxima™ Hip
Other group
Description:
A short, anatomic, cementless femoral component for use in total hip arthroplasty
Treatment:
Device: DePuy Proxima™ Hip

Trial contacts and locations

4

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems